Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 701-706

  Hoelzer, Dieter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

antigen expression on acute lymphoblastic leukemia cells; leukemia specific cellular therapies; monoclonal or bispecific antibodies

Indexed keywords

ALEMTUZUMAB; BLINATUMOMAB; CALICHEAMICIN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD52 ANTIGEN; CLOFARABINE; CYTARABINE; EPRATUZUMAB; GEMTUZUMAB; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; OZOGAMICIN; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL; BORDERLINE HYPERTENSION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; CYTOKINE RELEASE SYNDROME; DISEASE FREE SURVIVAL; FEVER; HUMAN; LEUKEMIA REMISSION; LIVER FUNCTION; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; VEIN OCCLUSION;

ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84885426867     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000009     Document Type: Review

References (23)

1. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29:532-543.
2. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010; 116:1165-1176.
3. Hoelzer D, Gökbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012; 26:25-32.
4. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 2012; 30:3876-3883.
5. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immuno-therapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011; 52:1098-1107.
6. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab in adult CD20 B-precusor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT. Haema-tologica 2009; 94:; abstract#481.
7. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28:3880-3889.
8. Hoelzer D, Goekbuget N, Beck J, et al. Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL) [abstract]. Blood 2004; 104:104-2732.
9. Angiolillo AL, Yu AL, Reaman G, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer 2009; 53:978-983.
10. Advani A, McDonough S, Coutre S, et al. Southwest Oncology Group Study S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia. ASH (Annual Meeting Abstracts) 2012; 120:2603.
11. Wayne Alan S, Bhojwani Deepa, Silverman Lewis B, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lym-phoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2011; 118:248.
12. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lympho-cytic leukaemia: a phase 2 study. Lancet Oncol 2012; 13:403-411.
13. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868-1876.
14. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-2498.
15. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-977.
16. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185-5187.
17. Topp MS, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2012; 120:670.
18. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119:6226-6233.
19. Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with posttransplant relapsed acute lymphoblastic leukemia. Leukemia 2011; 25:181-184.
20. Rettinger E, Kuçi S, Naumann I, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012; 14:91-103.
21. Linn YC, Niam M, Chu S, et al. The antitumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2012; 47:957-966.
22. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-1518.
23. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lympho-blastic leukemia. Sci Transl Med 2013; 5:177ra38.